Immune adverse outcome pathways (Homo sapiens)
From WikiPathways
Description
AOP of immune activation
Quality Tags
Ontology Terms
Bibliography
No bibliography
History
View all... |
External references
DataNodes
View all... |
Name | Type | Database reference | Comment |
---|---|---|---|
Hyperinflammation | 1868 (AOP-Wiki KE) | ||
Apoptosis modulation and signaling | Pathway | WP1772 (WikiPathways) | |
Apoptosis | Pathway | WP254 (WikiPathways) | |
Binding to ACE2 | 1739 (AOP-Wiki KE) | ||
Cytokine release syndrome | |||
Cytokine storm syndrome | Pathway | WP5257 (WikiPathways) | |
Endothelial cell activation | |||
IL-2 signaling pathway | Pathway | WP49 (WikiPathways) | |
Increase, Cell death | 1825 (AOP-Wiki KE) | ||
Increased SARS-CoV-2 production | 1847 (AOP-Wiki KE) | ||
Increased, recruitment of inflammatory cells | 1497 (AOP-Wiki KE) | ||
Increased, secretion of proinflammatory mediators | 1496 (AOP-Wiki KE) | ||
Interferon-I antiviral response, antagonized by SARS-CoV-2 | 1901 (AOP-Wiki KE) | ||
Leukocyte recruitment | |||
Macrophage markers | Pathway | WP4146 (WikiPathways) | |
Overview of proinflammatory and profibrotic mediators | Pathway | WP5095 (WikiPathways) | |
Pro-inflammatory mediators | |||
Recognition of AEC | |||
SARS coronavirus and innate immunity | Pathway | WP4912 (WikiPathways) | |
SARS-CoV-2 cell entry | 1738 (AOP-Wiki KE) | ||
Soluble ACE2-mediated cell entry of SARS-CoV-2 | Pathway | WP5076 (WikiPathways) | |
Systemic inflammation | |||
T-cell receptor signaling pathway | Pathway | WP69 (WikiPathways) | |
TNF-alpha signaling pathway | Pathway | WP231 (WikiPathways) | |
Type II interferon signaling | Pathway | WP619 (WikiPathways) |
Annotated Interactions
No annotated interactions